Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.46 |
| ▸ | PNLIP | P16233 | 2/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | ESRRA | P11474 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25353868 | 0.87 | ERBB2 (0.56) | EPHX2NR1H4ERBB2MAPK14MEN1 | |
| SCHEMBL3484767 | 0.84 | ACACB (0.43) | EPHX2NR1H4ERBB2PNLIP | |
| SCHEMBL3509494 | 0.82 | ALDH1A1 (0.62) | PDE7AALDH1A1SMN1; SMN2MEN1LMNA | |
| SCHEMBL3507398 | 0.80 | MRGPRX4 (0.46) | EPHX2NR1H4ERBB2PTGDR2ALDH1A1 | |
| SCHEMBL2748866 | 0.78 | ESRRA (0.45) | EPHX2NR1H4PNLIPESRRAPDE7A | |
| SCHEMBL27684228 | 0.76 | PDE7A (0.46) | EPHX2NR1H4PNLIPESRRAPDE7A | |
| SCHEMBL16492362 | 0.75 | PDE7A (0.49) | PNLIPPDE7AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL28880745 | 0.74 | PNLIP (0.46) | NR1H4PNLIPESRRAPDE7AMEN1 | |
| SCHEMBL3484062 | 0.73 | ERBB2 (0.46) | ERBB2 | |
| SCHEMBL10323127 | 0.72 | KDM4E (0.65) | EPHX2NR1H4ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-1987037-A2 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007097470-A2 | FUSED NITROGEN- COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | NR0B2, NR0B1, NR4A3 | EPHX2 1987/4885NR1H4 746/4885ERBB2 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.